Marin Software (NASDAQ: MRIN) +20%; announced an integration with Criteo's Commerce Media Platform. The integration will allow brands to easily manage and optimize both Criteo Marketing Solution and Retail Media campaigns—from display advertisements on the open web to promoted products on leading retailer websites—all within the MarinOne platform.

Marker Therapeutics (NASDAQ: MRKR) +15%; today announced that the Company received notice of a Product Development Research award totaling approximately $13.1 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to support the Company's Phase 2 clinical trial of its lead MultiTAA-specific T cell product MT-401.

Foot Locker (NYSE: FL) +10.5%; reported Q2 EPS of $2.21, $1.21 better than the analyst estimate of $1.00. Revenue for the quarter came in at $2.28 billion versus the consensus estimate of $2.08 billion.

Naked Brand Group Limited (NASDAQ: NAKD) +10%; Chairman addresses annual meeting of shareholders.

Progenity (NASDAQ: PROG) -52%; announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.

Endo International (NASDAQ: ENDP) -30%; tapped a financial restructuring adviser to help it evaluate its options for dealing with thousands of lawsuits alleging its contributed to the opioid crisis, according to a report from Dow Jones, citing people familiar with the matter

Fate Therapeutics (NASDAQ: FATE) -16%; highlighted positive interim clinical data from the Company’s FT516 and FT596 programs for patients with relapsed / refractory B-cell lymphoma. FT516 is the Company’s universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, which is designed to maximize antibody-dependent cellular cytotoxicity (ADCC), a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells. The Company’s FT596 program incorporates both the hnCD16 Fc receptor and a chimeric antigen receptor (CAR) targeting CD19, which is designed to enable multi-antigen targeting of tumor cells, as well as an IL-15 receptor fusion (IL-15RF) to enhance NK cell activity and survival.

Mudrick Capital Acquisition Corp. II (NASDAQ: MUDS) -2%; announced today that the Agreement and Plan of Merger with Topps Intermediate Holdco, Inc. and Tornante-MDP Joe Holding LLC has been terminated by mutual agreement, after notification on August 19, 2021 from Major League Baseball and the Major League Baseball Players Association that they would not be renewing their respective agreements with The Topps Company when they come up for renewal at the end of 2025 and 2022, respectively.